Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Amit Sanyal, MD: A Clinician’s Perspective

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

May

Today In Oncology

Addition of Durvalumab to Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer PROs in TOPAZ-1

Omission of Axillary Dissection After Nodal Downstaging With Neoadjuvant Chemotherapy in Breast Cancer

Local Recurrence of Endometrial Cancer Radiotherapy With or Without Cisplatin

Historical Community Outreach and Engagement Efforts at NCI-Designated Cancer Centers

Newly Identified Biomarkers May Improve Diagnosis and Treatment of RCC Subtypes